In NSCLC, the presence of EGFR mutations is associated with a lower response rate and a worse outcome under ICP whereas a high TMB is correlated with a better response, making TMB a predictive biomarker of ICP response (51, 52). This evidence concerns the gene EGFR and non-small cell lung carcinoma.